Weekly injections of semaglutide over 26 weeks were more effective than matching placebo in improving glycemic control and weight outcomes in patients with schizophrenia who received clozapine or olanzapine, a randomized trial has found. Participants receiving semaglutide did not experience a disproportionate number of adverse events. Study results were published online Dec. 3, 2025 in JAMA Psychiatry .
A Mon, study studied this question.